HTGM(Delisted)
Htg Molecular Diagnostics·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HTGM
Htg Molecular Diagnostics, Inc.
A life science company that develops technology for molecular profiling including tumor profiling, diagnostic of cancer, and other diseases
3430 E. Global Loop, Tucson, AZ 85706
--
Htg Molecular Diagnostics, Inc. is a commercial stage company that develops and sells a new technology platform for complex molecular profiling for routine use. Its HTG edge automation platform can quickly, robustly and simultaneously profile thousands of clinically relevant molecular targets from samples in a fraction of the size required by current technology. Their goal is to establish a standard for molecular analysis of the HTG edge platform, making this function available to all molecular laboratories from research to clinical. The functionality of its platform also enables biopharmaceutical companies and research centers to better harness the power of molecular analysis in their preclinical and clinical applications.
Company Financials
EPS
HTGM has released its 2023 Q1 earnings. EPS was reported at -2.28, versus the expected -1.94, missing expectations. The chart below visualizes how HTGM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HTGM has released its 2023 Q1 earnings report, with revenue of 1.03M, reflecting a YoY change of -12.83%, and net profit of -5.05M, showing a YoY change of 22.20%. The Sankey diagram below clearly presents HTGM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
